The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008A Novel Cell Model for LRRK2 Parkinson's Disease
Objective/Rationale:
The aim of this project is to create a model of Parkinson’s disease using skin cells from patients who have an inherited form of Parkinson’s disease. Using newly developed stem... -
Rapid Response Innovation Awards, 2008Identification of binding proteins for alpha-synuclein oligomers in brain and cells
Mutations in the PARK-1 and PARK-4 genes leads to alpha-synuclein aggregation with pathology eventually resembling that of sporadic PD. One question is whether the insoluble form of alpha-synuclein is...
-
Target Validation, 2007Validation of Sirtuin 2 Deacetylase as a Therapeutic Target in Parkinson’s disease
Objective/Rationale:
A major known risk factor in Parkinson’s disease is the misfolding, aggregation and abnormal accumulation of the protein alpha-synuclein. The goal of the proposed work is to... -
Rapid Response Innovation Awards, 2007Understanding the Role of Glucocerebrosidase in Parkinson's Disease Pathogenesis: Toward a New Genetic Model of Sporadic PD
Gaucher’s disease is a glycosphingolipid-storage disease in which homozygous mutations are found in the lysosomal enzyme glucocerebrosidase (GBA) gene. PD and Gaucher’s disease share many clinical and...
-
Rapid Response Innovation Awards, 2007Target Identification of the Mitochondrial Parkinson's Disease PTEN-Induced Kinase 1
Mutations in PINK1 can cause Parkinson’s disease in certain familial PD cases. The exact cellular function of PINK1 and the impact of disease-relevant mutations remain unknown. PINK1 is known to...
-
Rapid Response Innovation Awards, 2007Development of SHG to Discover Drugs to Selectively Block AlphaS toxicity
Abnormal aggregation of normal or genetically mutated alpha-synuclein protein has been proposed as one possible mechanism for PD. Drugs that can target this abnormal change in the structure of the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.